Caseware UK (AP4) 2024.0.164 2024.0.164 2025-03-31 2025-03-31 2024-04-01 true false false No description of principal activity 9 9 false The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006. 01597645 2024-04-01 2025-03-31 01597645 2023-04-01 2024-03-31 01597645 2025-03-31 01597645 2024-03-31 01597645 2023-04-01 01597645 c:Director1 2024-04-01 2025-03-31 01597645 d:Buildings d:LongLeaseholdAssets 2024-04-01 2025-03-31 01597645 d:Buildings d:LongLeaseholdAssets 2025-03-31 01597645 d:Buildings d:LongLeaseholdAssets 2024-03-31 01597645 d:PlantMachinery 2024-04-01 2025-03-31 01597645 d:PlantMachinery 2025-03-31 01597645 d:PlantMachinery 2024-03-31 01597645 d:PlantMachinery d:OwnedOrFreeholdAssets 2024-04-01 2025-03-31 01597645 d:MotorVehicles 2024-04-01 2025-03-31 01597645 d:MotorVehicles 2025-03-31 01597645 d:MotorVehicles 2024-03-31 01597645 d:MotorVehicles d:OwnedOrFreeholdAssets 2024-04-01 2025-03-31 01597645 d:OwnedOrFreeholdAssets 2024-04-01 2025-03-31 01597645 d:CurrentFinancialInstruments 2025-03-31 01597645 d:CurrentFinancialInstruments 2024-03-31 01597645 d:Non-currentFinancialInstruments 2025-03-31 01597645 d:Non-currentFinancialInstruments 2024-03-31 01597645 d:CurrentFinancialInstruments d:WithinOneYear 2025-03-31 01597645 d:CurrentFinancialInstruments d:WithinOneYear 2024-03-31 01597645 d:Non-currentFinancialInstruments d:AfterOneYear 2025-03-31 01597645 d:Non-currentFinancialInstruments d:AfterOneYear 2024-03-31 01597645 d:ShareCapital 2024-04-01 2025-03-31 01597645 d:ShareCapital 2025-03-31 01597645 d:ShareCapital 2024-03-31 01597645 d:ShareCapital 2023-04-01 01597645 d:RetainedEarningsAccumulatedLosses 2024-04-01 2025-03-31 01597645 d:RetainedEarningsAccumulatedLosses 2025-03-31 01597645 d:RetainedEarningsAccumulatedLosses 2023-04-01 2024-03-31 01597645 d:RetainedEarningsAccumulatedLosses 2024-03-31 01597645 d:RetainedEarningsAccumulatedLosses 2023-04-01 01597645 c:OrdinaryShareClass1 2024-04-01 2025-03-31 01597645 c:OrdinaryShareClass1 2025-03-31 01597645 c:OrdinaryShareClass1 2024-03-31 01597645 c:FRS102 2024-04-01 2025-03-31 01597645 c:AuditExempt-NoAccountantsReport 2024-04-01 2025-03-31 01597645 c:FullAccounts 2024-04-01 2025-03-31 01597645 c:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 01597645 d:HirePurchaseContracts d:WithinOneYear 2025-03-31 01597645 d:HirePurchaseContracts d:WithinOneYear 2024-03-31 01597645 d:HirePurchaseContracts d:BetweenOneFiveYears 2025-03-31 01597645 d:HirePurchaseContracts d:BetweenOneFiveYears 2024-03-31 01597645 2 2024-04-01 2025-03-31 01597645 6 2024-04-01 2025-03-31 01597645 e:PoundSterling 2024-04-01 2025-03-31 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 01597645 WELBECK PHARMACEUTICALS & HOSPITAL SUPPLIES LIMITED UNAUDITED FINANCIAL STATEMENTS INFORMATION FOR FILING WITH THE REGISTRAR FOR THE YEAR ENDED 31 MARCH 2025
WELBECK PHARMACEUTICALS & HOSPITAL SUPPLIES LIMITED REGISTERED NUMBER: 01597645 STATEMENT OF FINANCIAL POSITION AS AT 31 MARCH 2025
|  | 2025 |  | 2024
Note |  | £ |  | £
Fixed assets |  |  |  |  |
Tangible fixed assets |  |  | 89,967 |  | 104,762
Current assets |  |  |  |  |
Stocks |  | 56,500 |  | 63,500 |
Debtors: amounts falling due within one year | 5 | 638,047 |  | 749,964 |
Bank and cash balances |  | 1,208,412 |  | 825,409 |
|  | 1,902,959 |  | 1,638,873 |
Creditors: amounts falling due within one year | 6 | (1,516,388) |  | (988,414) |
Net current assets |  |  | 386,571 |  | 650,459
Creditors: amounts falling due after more than one year | 7 |  | (19,534) |  | (45,580)
Net assets |  |  | 457,004 |  | 709,641
Capital and reserves |  |  |  |  |
Called up share capital | 9 |  | 25,500 |  | 50,000
Profit and loss account |  |  | 431,504 |  | 659,641
|  |  | 457,004 |  | 709,641
The directors consider that the company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006. The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements. The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities. The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. The company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime. The financial statements were approved and authorised for issue by the board and were signed on its behalf on 4 February 2026.
A A Wahab
Director
The notes on pages 4 to 8 form part of these financial statements. Page 1
WELBECK PHARMACEUTICALS & HOSPITAL SUPPLIES LIMITED REGISTERED NUMBER: 01597645 STATEMENT OF FINANCIAL POSITION (CONTINUED) AS AT 31 MARCH 2025 Page 2

|  | WELBECK PHARMACEUTICALS & HOSPITAL SUPPLIES LIMITED |
STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 31 MARCH 2025
|  | Called up share capital | Profit and loss account | Total equity
|  | £ | £ | £
| At 1 April 2023 | 50,000 | 267,057 | 317,057
| Profit for the year | - | 412,584 | 412,584
| Dividends: Equity capital | - | (20,000) | (20,000)
| At 1 April 2024 | 50,000 | 659,641 | 709,641
| Profit for the year | - | 197,363 | 197,363
| Purchase of own shares | - | (425,500) | (425,500)
| Shares cancelled during the year | (24,500) | - | (24,500)
| At 31 March 2025 | 25,500 | 431,504 | 457,004
| The notes on pages 4 to 8 form part of these financial statements.
Page 3

WELBECK PHARMACEUTICALS & HOSPITAL SUPPLIES LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025
1. | General information
Welbeck Pharmaceuticals & Hospital Supplies Limited is a private company limited by shares incorporated in England and Wales. The registered office is 35 Devonshire Street, London, W1G 6PZ. 2.Accounting policies
| 2.1 | Basis of preparation of financial statements
The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the requirements and the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view. The following principal accounting policies have been applied:
| 2.2 | Revenue
Turnover is recognised at the fair value of the consideration received or receivable for goods provided in the normal course of business, and is shown net of VAT and other sales related taxes. Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.
| 2.3 | Interest income
Interest income is recognised in profit or loss using the effective interest method.
| 2.4 | Finance costs
Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.
| 2.5 | Pensions
Defined contribution pension plan The company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the company pays fixed contributions into a separate entity. Once the contributions have been paid the company has no further payment obligations. The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Statement of Financial Position. The assets of the plan are held separately from the company in independently administered funds. Page 4
WELBECK PHARMACEUTICALS & HOSPITAL SUPPLIES LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025 2.Accounting policies (continued)
| 2.6 | Tangible fixed assets
Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management. Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, on a reducing balance basis. Depreciation is provided on the following basis:
|  |  |  | Long-term leasehold property | - | Straight line over the term of the lease
|  |  |  | Plant and machinery | - | 15% reducing balance
|  |  |  | Motor vehicles | - | 15% reducing balance
The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date. Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.
| 2.7 | Foreign currency
Functional and presentational currency The company's functional and presentational currency is GBP.
| 2.8 | Stocks
Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. At each reporting date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.
| 2.9 | Debtors
Short term debtors are measured at transaction price, less any impairment
| 2.10 | Cash and cash equivalents
Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours.
| 2.11 | Creditors
Short term creditors are measured at the transaction price. Page 5
WELBECK PHARMACEUTICALS & HOSPITAL SUPPLIES LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025 2.Accounting policies (continued)
| 2.12 | Operating leases: the company as lessee
Rentals paid under operating leases are charged to profit or loss on a straight-line basis over the lease term.
| 2.13 | Dividends
Equity dividends are recognised when they become legally payable.
3. | Employees
| The average monthly number of employees, including directors, during the year was 9 (2024 - 9).
4. | Tangible fixed assets
|  | Long-term leasehold property | Plant and machinery | Motor vehicles | Total
|  | £ | £ | £ | £
| Cost or valuation |  |  |  |
| At 1 April 2024 | 195,246 | 212,115 | 90,642 | 498,003
| Additions | - | 1,148 | - | 1,148
| At 31 March 2025 | 195,246 | 213,263 | 90,642 | 499,151
| Depreciation |  |  |  |
| At 1 April 2024 | 192,956 | 196,320 | 3,965 | 393,241
| Charge for the year on owned assets | 398 | 2,543 | 13,002 | 15,943
| At 31 March 2025 | 193,354 | 198,863 | 16,967 | 409,184
| Net book value |  |  |  |
| At 31 March 2025 | 1,892 | 14,400 | 73,675 | 89,967
| At 31 March 2024 | 2,290 | 15,795 | 86,677 | 104,762
Page 6
WELBECK PHARMACEUTICALS & HOSPITAL SUPPLIES LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025
5. | Debtors
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
| Trade debtors | 466,054 | 603,899
| Other debtors | 72,586 | 51,055
| Prepayments and accrued income | 99,407 | 95,010
|  | 638,047 | 749,964
6. | Creditors: Amounts falling due within one year
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
| Trade creditors | 149,681 | 168,354
| Corporation tax | 23,092 | 81,928
| Other taxation and social security | 55,182 | 53,726
| Obligations under finance lease and hire purchase contracts | 26,046 | 26,046
| Other creditors | 1,262,387 | 658,360
|  | 1,516,388 | 988,414
7. | Creditors: Amounts falling due after more than one year
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
| Net obligations under finance leases and hire purchase contracts | 19,534 | 45,580
8. | Hire purchase and finance leases
| Minimum lease payments under hire purchase fall due as follows:
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
| Within one year | 26,046 | 26,046
| Between 1-5 years | 19,534 | 45,580
|  | 45,580 | 71,626
Page 7
WELBECK PHARMACEUTICALS & HOSPITAL SUPPLIES LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025
9. | Share capital
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
|  | Allotted, called up and fully paid |  |
|  | 25,500 (2024 - 50,000) Ordinary shares of £1.00 each | 25,500 | 50,000
10. | Pension commitments
The company operates a defined contributions pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. The pension cost charge represents contributions payable by the company to the fund and amounted to £3,360 (2024 - £123,493).
11. | Related party transactions
| At the year end the company owed £22,0445 (2024: £110,893) to its directors. The amount due is interest free and deemed repayable on demand.
12. | Controlling party
The company is controlled by Mr A Wahab and Mr O Wahab who together own 100% of the share capital.
Page 8